© 2004 by BMJ Publishing Group & British Cardiac Society
JournalScan
| The first 150 words of the full text of this article appear below. |
ISCHAEMIC HEART DISEASE

In the UK at least, low molecular weight heparin (LMWH) rather than unfractionated heparin has become the standard of care in acute coronary syndromes (ACS). In the A phase of the A to Z trial, which involved nearly 4000 patients treated with aspirin and tirofiban, the primary end point (a seven day composite of death, myocardial infarction (MI), or refractory ischaemia) occurred in 8.4% of patients assigned to receive enoxaparin compared to 9.4% in those receiving unfractionated heparin (hazard ratio (HR) 0.88, 95% confidence interval (CI) 0.71 to 1.08). SYNERGY looked at the use of LMWH versus conventional heparin in more than 10000 patients whose ACS was also treated with an early invasive strategy. Their primary end point (30 day composite of death or MI) occurred in 14.0% of patients assigned to enoxaparin versus 14.5% receiving conventional heparin (HR 0.96, 95% CI 0.86 to 1.06). Again, the authors summary stated
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
